Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
about
Comparison of allogeneic stem cell transplantation and non-transplant approaches in elderly patients with advanced myelodysplastic syndrome: optimal statistical approaches and a critical appraisal of clinical results using non-randomized data.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsTreatment of acute myeloid leukemia in older patients.Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donorPretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaBusulfan in hematopoietic stem cell transplant setting.High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.Reduced intensity conditioning of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia in patients older than 50 years of age: a systematic review and meta-analysis.Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia.Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes.Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies
P2860
Q30675919-E7A1AB2E-0A1A-49DF-A896-31C8208A220BQ33771667-C73C2EB7-86EF-4AAF-B898-4625B077750CQ34185528-C1BAA32C-6F82-4E78-9718-499E1CC12295Q34284225-73B766B7-F884-4E5B-9B65-BB3FD6D308FAQ35193735-2C056D4D-7272-4C57-A8F1-1E48537AA096Q35838113-4D50FF72-287C-41A2-86E0-D0D4CAE20437Q36752023-C0B8B671-760B-4296-A574-758667EE9BCBQ36824553-C9AB6222-5118-42C4-89FC-7A75FC18299EQ37085064-805C949F-2450-4E87-A7C5-1EE424652A6AQ37270982-29782C6F-D57B-4973-B1BE-6179B235A1B2Q37554387-13557471-87DE-4654-B254-A04AFED4A3C8Q37788219-D16F7212-9432-4A23-9FCD-5ECC84A4430CQ37863461-8D0211DA-A5C4-4815-B896-A5F046505A57Q37955235-DBDD380D-771A-4C08-84E4-3A8F72CB57F6Q38479720-B3AFEA99-4D6B-485C-8CAF-4E7F02C38C2CQ39282540-57045228-22DE-47F8-8756-30A1FADD3395Q39306717-01CC915D-DCCF-4A1A-8CB4-2407DC62F08FQ39901701-3D33F1C7-2D00-4977-BA93-FFC5A2DCA658Q40280061-5ABC5E61-5BE7-4F94-9F6D-D375BA31DA76Q41363547-E33691EC-000E-4F09-B916-88D3CCBAD81BQ43692529-5F5D64E4-82C0-469B-8352-86D7C5CA9281Q46860359-A1A94E6D-4976-4846-96F7-A8F8F98EF907Q47724804-3FAA6194-65CF-4B01-927C-9F265E131169Q52881184-773CE9D8-7EED-490D-8B40-057DCBF680D7Q57636771-2FE83CF9-A1CB-4A04-944F-DC2D70349062
P2860
Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@en
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@nl
type
label
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@en
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@nl
prefLabel
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@en
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@nl
P2093
P2860
P356
P1476
Reduced-toxicity conditioning ...... yelodysplastic syndrome (MDS).
@en
P2093
Atanackovic D
Schieder H
Wolschke C
P2860
P2888
P304
P356
10.1038/SJ.BMT.1705259
P407
P577
2006-02-01T00:00:00Z